Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer.
breast cancer
ceruloplasmin
immune infiltration
iron
prognosis
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
19 08 2021
19 08 2021
Historique:
received:
30
01
2021
accepted:
02
08
2021
pubmed:
21
8
2021
medline:
2
2
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Breast-invasive carcinoma (BRCA) is the most frequent and malignant tumor in females. Ceruloplasmin (CP) is a multifunctional molecule involved in iron metabolism, but its expression profile, prognostic potential and relationship with immune cell infiltration in BRCA are unknown. Ceruloplasmin mRNA and protein expression was significantly decreased in BRCA patients according to the Oncomine, UALCAN, GEPIA and TCGA databases. Ceruloplasmin expression was strongly correlated with various clinicopathological features of BRCA patients. BRCA patients with high ceruloplasmin expression exhibited shorter survival times than those with low ceruloplasmin expression based on the Kaplan-Meier plotter and PrognoScan databases. GO and KEGG analyses and GSEA revealed a strong correlation between ceruloplasmin and various immune-related pathways. Ceruloplasmin expression was significantly associated with the infiltration of immune cells into tumor sites by analyzing the TIMER and CIBERSORT. Additionally, ceruloplasmin was positively correlated with immune checkpoints in BRCA. These findings suggest that low ceruloplasmin expression correlates with a favorable prognosis and tumor immune cell infiltration in BRCA patients. Ceruloplasmin may serve as a therapeutic target and predict the efficacy of immunotherapy for BRCA.
Identifiants
pubmed: 34413268
pii: 203427
doi: 10.18632/aging.203427
pmc: PMC8436892
doi:
Substances chimiques
Biomarkers, Tumor
0
Ceruloplasmin
EC 1.16.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20438-20467Références
Cancer Sci. 2009 May;100(5):970-7
pubmed: 19298223
Mol Med Rep. 2017 Dec;16(6):8371-8379
pubmed: 28983631
J Endocrinol Invest. 2012 Jun;35(6):566-9
pubmed: 21795842
Mol Oncol. 2021 Aug;15(8):2084-2105
pubmed: 33675143
Oxid Med Cell Longev. 2017;2017:3793817
pubmed: 28280523
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
Tumour Biol. 2016 Jul;37(7):9709-19
pubmed: 26803514
Biometals. 2020 Oct;33(4-5):201-215
pubmed: 32757166
Blood. 2005 Jun 15;105(12):4613-9
pubmed: 15741220
Oncotarget. 2017 Apr 25;8(17):29028-29037
pubmed: 28423673
Lung Cancer. 2018 Apr;118:97-104
pubmed: 29572010
Front Endocrinol (Lausanne). 2018 Sep 27;9:552
pubmed: 30319540
Oral Dis. 2017 Nov;23(8):1066-1071
pubmed: 28513913
Acta Med Okayama. 2020 Feb;74(1):1-6
pubmed: 32099242
Front Cell Dev Biol. 2020 Nov 19;8:589016
pubmed: 33330467
Breast Cancer. 2017 Mar;24(2):191-219
pubmed: 27796923
Exp Biol Med (Maywood). 2009 Jun;234(6):693-702
pubmed: 19307463
J Biol Chem. 2003 Jul 18;278(29):27144-8
pubmed: 12743117
J Endocrinol. 2013 Feb 15;216(3):273-85
pubmed: 23169992
EMBO J. 2007 Jun 20;26(12):2823-31
pubmed: 17541408
Cancer Lett. 1997 Dec 23;121(2):139-45
pubmed: 9570351
Biol Reprod. 1999 Oct;61(4):1042-9
pubmed: 10491642
Nat Commun. 2016 Jun 29;7:11996
pubmed: 27353863
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
Indian J Med Sci. 2004 Apr;58(4):150-4
pubmed: 15122050
Aging (Albany NY). 2021 Mar 10;13(6):8737-8761
pubmed: 33714956
Front Oncol. 2019 Oct 15;9:1067
pubmed: 31681600
Annu Rev Nutr. 2002;22:439-58
pubmed: 12055353
Nat Commun. 2019 Aug 20;10(1):3739
pubmed: 31431624
Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):846-857
pubmed: 31054961
J Proteome Res. 2014 Jun 6;13(6):2887-96
pubmed: 24799124
Biochim Biophys Acta Gen Subj. 2021 Sep;1865(9):129952
pubmed: 34147543
Int Immunopharmacol. 2020 Dec;89(Pt B):107078
pubmed: 33049497
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Acta Med Okayama. 1986 Apr;40(2):103-5
pubmed: 3716874
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
Int J Mol Sci. 2019 Jan 11;20(2):
pubmed: 30641920
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
Nat Commun. 2015 Mar 12;6:6580
pubmed: 25762445
Clin Biochem. 2011 Apr;44(5-6):351-6
pubmed: 21291874
Int J Obes Relat Metab Disord. 1996 Sep;20(9):809-13
pubmed: 8880346
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10812-7
pubmed: 10485908
Blood Cells Mol Dis. 2012 Feb 15;48(2):110-20
pubmed: 22178061
J Biol Chem. 1989 Apr 15;264(11):6183-7
pubmed: 2539373
J Biol Chem. 1988 May 5;263(13):6281-7
pubmed: 3360784
J Trace Elem Med Biol. 2019 Dec;56:52-59
pubmed: 31442954
Cell Mol Life Sci. 2002 Sep;59(9):1413-27
pubmed: 12440766
Urol Oncol. 2016 Apr;34(4):168.e1-9
pubmed: 26670202
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pathol Oncol Res. 2014 Jan;20(1):119-29
pubmed: 23925487
J Cell Mol Med. 2020 Jan;24(1):202-213
pubmed: 31668012
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Int J Mol Sci. 2018 Dec 27;20(1):
pubmed: 30591630
J Cancer. 2018 Apr 30;9(11):2012-2023
pubmed: 29896286
PLoS One. 2014 Mar 27;9(3):e80274
pubmed: 24676332
J Biol Chem. 1966 Jun 25;241(12):2746-51
pubmed: 5912351
Am J Physiol. 1974 Nov;227(5):1094-7
pubmed: 4440750
J Biol Chem. 1997 Aug 8;272(32):20185-90
pubmed: 9242695
Int J Mol Sci. 2020 Jul 18;21(14):
pubmed: 32708433